Program
THB335
A development code. Also written as “THB335 Lower Dose”, “THB335 Higher Dose” and “THB335 single dose”.
Its studies are mostly in Chronic Urticaria, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Calixis | 11 open or running | phase 2since Aug 11, 2026 | Aug 11, 2026 | Dec 31, 2027phase 2 · NCT07766499 |
| Third Harmonic Bio | 10 open or running | phase 1since May 15, 2024 | May 15, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 15, 2024First study: phase 1 study in HealthyNew to Third Harmonic BioThird Harmonic Bio · NCT06425861 · 60 enrolled · United States
- Aug 11, 2026Calixis's first study: phase 2 study in Chronic UrticariaNew to CalixisCalixis · NCT07766499 · 81 planned · United States
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Chronic UrticariaCalixis · NCT07766499
TargetBeta
“THB335 is a highly potent and selective inhibitor of the receptor tyrosine kinase KIT that is expressed on mast cells.”study text, by rule · the study
Other programs on KIT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Avapritinibrule | Sanofi | phase 4 | 10 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 9 |
| velzatinib | GlaxoSmithKline | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| elenestinib | Sanofi | phase 3 | 3 |
| NB-003rule | ningbo-newbay-technology-development-co-ltd | phase 3 | 2 |
| briquilimabrule | jasper-therapeutics-inc | phase 2 | 7 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07766499Chronic Urticaria · United States | 2 | Recruiting | Calixis | Dec 31, 2027 | 81 |
| NCT06425861Healthy · United States | 1 | Completed | Third Harmonic Bio | Dec 18, 2024 | 60 |
How it is read
Names in the registry
- “THB335 Lower Dose”, 1 entry
- “THB335 Higher Dose”, 1 entry
- “THB335 single dose”, 1 entry
- “THB335 fasted/fed”, 1 entry
- “THB335 multiple dose”, 1 entry
Codes read as this program: THB335.
Conditions, from the studies’ own filings
- Chronic Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.